SureTrader SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Neurotrope Inc. (NTRPD)

NTRPD RSS Feed
Add NTRPD Price Alert      Hide Sticky   Hide Intro
Moderator: bUrRpPPP!, PatrickBateman, kld2
Search This Board:
Last Post: 1/19/2017 9:28:00 PM - Followers: 44 - Board type: Free - Posts Today: 0

NTRPD Security Details
Share Structure


Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017
 

Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million

 

NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

NTRP Security Details
Share Structure
Shareholders
Shareholders of Record Not Available
Corporate Actions
  Ex. Date Record Date Pay Date
Security Notes
Short Selling Data
Short Interest (%)
Significant Failures to Deliver No
Transfer Agent(s)
Philadelphia Stock Transfer, Inc.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRPD
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#254  Sticky Note Eli Lilly, Biogen, and Neurotrope Fight to Find bUrRpPPP! 01/14/17 12:34:07 PM
#273   Makes sense. HANUMAN 01/19/17 09:27:59 PM
#272   Said the 20 mil will give them more 21money21 01/19/17 09:23:38 PM
#271   Actually I remember reading that now. Brain HANUMAN 01/19/17 09:01:59 PM
#270   This article should give you a much clearer bUrRpPPP! 01/19/17 08:25:10 PM
#269   Just raised $20 mil... 21money21 01/19/17 08:15:55 PM
#268   NTRPD reported 6.52m cash at end of 3rd HANUMAN 01/19/17 06:19:47 PM
#267   Share structure confirmed by transfer agent....new update in IBOX... bUrRpPPP! 01/19/17 11:32:12 AM
#266   Thanks for your share structure updates. Added HANUMAN 01/19/17 11:27:27 AM
#265   Share structure update.... bUrRpPPP! 01/19/17 11:02:47 AM
#264   What a turd. TheDoc01 01/18/17 11:45:30 AM
#263   I got some at 7.15, will get more Rymankoly 01/17/17 08:10:27 PM
#262   .22 pre split today. I wonder at what porgyrusty 01/17/17 06:23:36 PM
#261   HA HA HA bogey999 01/17/17 05:20:01 PM
#260   Warrants Pre-split there were 125m@.40 which would now bUrRpPPP! 01/15/17 03:39:54 PM
#259   Warrants? How many fully diluted shares outstanding? I DendriteResearch 01/15/17 02:51:43 PM
#258   Great article, thanks for posting Sendme 01/14/17 07:25:00 PM
#257   This paragraph in your cited story makes me HANUMAN 01/14/17 06:31:14 PM
#256   I'll do. Thanks. kld2 01/14/17 12:39:16 PM
#255   KLD2...please request to become a moderator so you bUrRpPPP! 01/14/17 12:37:56 PM
#254   Eli Lilly, Biogen, and Neurotrope Fight to Find bUrRpPPP! 01/14/17 12:34:07 PM
#253   another article: kld2 01/14/17 09:56:18 AM
#252   Anyone know if NTRPD plans on presenting Ph2 kld2 01/14/17 09:20:09 AM
#251   I asked Neurotrope IR about Compassionate Use studies. kld2 01/14/17 06:12:33 AM
#250   Actually its been above average volume the last runncoach 01/13/17 03:52:22 PM
#249   Thank you pennymonster1 01/13/17 03:30:16 PM
#248   is that why you're posting? To the no-souls. kld2 01/13/17 02:47:01 PM
#247   Just saw a tweet by the guy with kld2 01/13/17 02:18:50 PM
#246   Not a soul seeing this as viable ARBITRARY & CAPRICIOUS 01/13/17 02:17:47 PM
#245   thanks Sean. kld2 01/13/17 01:53:28 PM
#244   I mean, I think I understand that much, kld2 01/13/17 01:48:29 PM
#243   Market cap does not change due to RS....market bUrRpPPP! 01/13/17 01:14:32 PM
#242   CEO statement was made after Ph2b enrollment was bUrRpPPP! 01/13/17 01:13:26 PM
#241   11.77M per Etrade @ $7.55 seanelliott 01/13/17 01:11:56 PM
#240   When did CEO make that statement? pennymonster1 01/13/17 01:01:21 PM
#239   This is a quiet board. Hopefully, after uplisting, kld2 01/13/17 12:37:03 PM
#238   What's the MC with R/S? kld2 01/13/17 11:59:18 AM
#237   Partner news on the horizon? bUrRpPPP! 01/13/17 09:52:26 AM
#236   Guide to NASDAQ Listing link.. takes about 5 weeks. bUrRpPPP! 01/12/17 05:26:15 PM
#235   Also new here, but still heavy in to HANUMAN 01/12/17 03:04:22 PM
#234   New here. Have been in AVXL for quite kld2 01/12/17 02:49:22 PM
#233   Thanks The D works PJO 01/12/17 10:19:59 AM
#232   That is generally the way it works. nsomniyak 01/12/17 08:47:05 AM
#231   I believe it trades under ntrpd for something 21money21 01/12/17 07:53:12 AM
#230   NTRPD $8.16 32-1 R/S effective today. All criteria bUrRpPPP! 01/12/17 07:18:09 AM
#229   Bartlman. I saw more penny stocks losing 50% than Rymankoly 01/11/17 08:21:50 PM
#228   Sorry Burp. Never said that you were an Bartlman 01/11/17 07:47:18 PM
#226   It already has ol' wise one. NTRP is bUrRpPPP! 01/11/17 07:25:29 PM
#225   LMFAO,,, your right I dont spend too much bUrRpPPP! 01/11/17 07:24:06 PM
#224   Thanx Squintz. You can get a stock on Bartlman 01/11/17 07:08:33 PM
#223   Not sure of the symbol change, but the SQUINTZ76 01/11/17 06:44:58 PM
PostSubject